Changing trend of antimicrobial resistance among pathogens isolated from lower respirator/tract at a university-affiliated hospital of China, 2006-2010

Journal of Thoracic Disease

Volumn 4, Issue 3, 2012, Pages 284-291

  Xia, Wenying ^a,b   Chen, Yi ^a   Mei, Yaning ^a,b   Wang, Tong ^a   Liu, Genyan ^a,b   Gu, Bing ^a,b   Pan, Shiyang ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Laboratory Medicine   (China)

Author keywords

Acinetobader; Antimicrobial resistance; Carbapenem; Lower respiratory tract; Staphylococcus aureus

Indexed keywords

AMOXICILLIN; AZTREONAM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLINDAMYCIN; ERYTHROMYCIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULPERAZON; SULTAMICILLIN; VANCOMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CANDIDA ALBICANS; CHINA; CITROBACTER; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FUNGUS; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; LOWER RESPIRATORY TRACT INFECTION; NONHUMAN; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; REVIEW; SPUTUM CULTURE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STENOTROPHOMONAS MALTOPHILIA; TREND STUDY; UNIVERSITY HOSPITAL;

EID: 84864468798     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2012.02.04     Document Type: Review

References (21)

1. Tao Y, Yan Z, Sha J, Zhu Z, Lei H. Severe gastroparesis causing postoperative respiratory complications in a heart-lung recipient. J Thorac Dis 2010;2:121-3.
2. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:867-903.
3. Kuba PK, Sharma J, Sharma AK. Complication of warfarin therapy presenting as empyema. J Triorac Dis 2011;3:74-6.
4. Gonlugur U, Bakici MZ, Akkurt I, Efeoglu T. Antibiotic susceptibility patterns among respiratory isolates of Gram-negative bacilli in a Turkish university hospital. BMC Microbiol 2004;4:32.
5. Mukhopadhyay C, Bhargava A, Ayyagari A. Role of mechanical ventilation & development of multidrug resistant organisms in hospital acquired pneumonia. Indian J Med Res 2003;118:229-35.
6. Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M, Ortqvist A, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005;26:1138-80.
7. Clinical and Laboratory Standards Institute. Analysis and presentation of cumulative susceptibility test data; approved guideline, 2nd ed. Document M39-A2, vol. 25, no. 28. Wayne (PA): Clinical and Laboratory Standards Institute; 2006.
8. Wang Y, Zhang R, Li W, Feng Y, Leng T. Serious antimicrobial resistance status of pathogens causing hospital-acquired lower respiratory tract infections in North China. J Int Med Res 2009;37:899-907.
9. Hoban DJ, Biedenbach DJ, Mutnick AH, Jones RN. Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Diagn Microbiol Infect Dis 2003;45:279-85.
10. Wang H, Yu Y, Xie X, Wang C, Zhang Y, Yuan Y, et al. In-vitro antibacterial activities of cefpiramide and other broad-spectrum antibiotics against 440 clinical isolates in China. J Infect Chemother 2000;6:81-5.
11. Glupczynski Y, Delmée M, Goossens H, Struelens M; Belgian Multicenter ICU Study Group. Distribution and prevalence of antimicrobial resistance among gram-negative isolates in intensive care units (ICU) in Belgian hospitals between 1996 and 1999. Acta Clin Belg 2001;56:297-306.
12. Barlow M, Hall BG. Experimental prediction of the natural evolution of antibiotic resistance. Genetics 2003;163:1237-41.
13. Xiao YH, Giske CG, Wei ZQ, Shen P, Heddini A, Li LJ. Epidemiology and characteristics of antimicrobial resistance in China. Drug Resist Updat 2011;14:236-50.
14. Li XZ, Poole K, Nikaido H. Contributions of MexAB-OprM and an EmrE homolog to intrinsic resistance of Pseudomonas aeruginosa to aminoglycosides and dyes. Antimicrob Agents Chemother 2003;47:27-33.
15. Kempf M, Rolain JM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents 2012;39:105-14.
16. Turner PJ. MYSTIC Europe 2007: activity of meropenem and other broadspectrum agents against nosocomial isolates. Diagn Microbiol Infect Dis 2009;63:217-22.
17. Mendes RE, Bell JM, Turnidge JD, Castanheira M, Jones RN. Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. J Antimicrob Chemother 2009;63:55-9.
18. Salyers AA, Whitt DD. Revenge of the microbes: how bacterial resistance is undermining the antibiotic miracle. Washington, DC: ASM Press; 2005.
19. Brotz-Oesterhelt H, Sass P. Postgenomic strategies in antibacterial drug discovery. Future Microbiol 2010;5:1553-79.
20. Woodford N, Livermore DM. Infections caused by Gram-positive bacteria: a review of the global challenge. J Infect 2009;59:S4-16.
21. Cao J, Song W, Gu B, Mei YN, Tang JP, Meng L, et al. Correlation Between Carbapenem Consumption and Antimicrobial Resistance Rates of Acinetobacter baumannii in a University-Affiliated Hospital in China. J Clin Pharmacol 2012. [Epub ahead of print].